Snupoxy (Spray) Instructions for Use
Marketing Authorization Holder
Nizhpharm JSC (Russia)
ATC Code
R01AA05 (Oxymetazoline)
Active Substance
Oxymetazoline (Rec.INN registered by WHO)
Dosage Forms
| Snupoxy | Metered nasal spray 11.25 mcg/dose | |
| Metered nasal spray 22.5 mcg/dose |
Dosage Form, Packaging, and Composition
Metered nasal spray
| 1 dose (45 µl) | |
| Oxymetazoline hydrochloride | 11.25 mcg |
10 ml (164 doses) – bottles – cardboard packs – Over-the-Counter
Metered nasal spray
| 1 dose (45 µl) | |
| Oxymetazoline hydrochloride | 22.5 mcg |
10 ml (164 doses) – bottles – cardboard packs – Over-the-Counter
Clinical-Pharmacological Group
Vasoconstrictor drug for topical use in ENT practice
Pharmacotherapeutic Group
Drugs for the treatment of nasal diseases; decongestants and other drugs for topical use; sympathomimetics
Pharmacological Action
Adrenomimetic agent for topical use. It has a vasoconstrictive effect. When applied intranasally, it reduces swelling of the mucous membrane of the upper respiratory tract.
Pharmacokinetics
When applied intranasally, T1/2 is 35 hours.
Indications
Nasal congestion in colds, sinusitis, eustachitis, hay fever, allergic rhinitis.
To relieve swelling before diagnostic procedures in the nasal passages.
ICD codes
| ICD-10 code | Indication |
| H68 | Inflammation and obstruction of Eustachian tube |
| J00 | Acute nasopharyngitis (common cold) |
| J01 | Acute sinusitis |
| J30.1 | Allergic rhinitis due to pollen |
| J30.3 | Other allergic rhinitis (perennial allergic rhinitis) |
| J31.0 | Chronic rhinitis (including ozaena, atrophic and hypertrophic rhinitis) |
| J32 | Chronic sinusitis |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| AB10.Z | Diseases of the auditory [eustachian] tube, unspecified |
| CA00 | Acute nasopharyngitis |
| CA01 | Acute rhinosinusitis |
| CA08.00 | Allergic rhinitis due to pollen |
| CA08.03 | Other allergic rhinitis |
| CA09.0 | Chronic rhinitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| QB9A | Preparatory procedures for subsequent treatment |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer intranasally after clearing the nasal passages.
For adults and children aged 6 years and older, use one injection of the 11.25 mcg/dose or 22.5 mcg/dose strength into each nostril.
Apply the spray no more than two to three times per day as needed for congestion relief.
The maximum duration of continuous use is 3 to 5 days.
Do not exceed the recommended dosage or duration of treatment to avoid rebound congestion (medication-induced rhinitis).
For children under 6 years of age, use only as directed by a physician and with an appropriate pediatric dosage form.
Prior to first use, prime the pump by pressing the actuator several times until a fine spray is produced.
To administer, keep the head upright, insert the tip into the nostril, and spray while breathing in gently through the nose.
Adverse Reactions
Local reactions possibly – burning, dryness of the nasal mucosa, sneezing; rarely – after the effect of the application wears off, the development of a strong feeling of nasal congestion (reactive hyperemia).
Systemic reactions multiple overdoses with topical application may lead to tachycardia and increased blood pressure; very rarely – anxiety, insomnia, fatigue, headaches, nausea.
Contraindications
Atrophic rhinitis, angle-closure glaucoma, hypersensitivity to oxymetazoline.
With caution
Use of MAO inhibitors and the period up to 10 days after their administration; use of drugs that promote an increase in blood pressure and the period up to 10 days after their administration; increased intraocular pressure; severe forms of cardiovascular diseases (arterial hypertension, coronary artery disease), thyrotoxicosis, diabetes mellitus, pregnancy, breastfeeding period.
Use in Pregnancy and Lactation
Use with caution during pregnancy and lactation (breastfeeding).
Pediatric Use
Used in children according to indications in appropriate dosage forms.
Geriatric Use
Use with caution in elderly patients to avoid exacerbation of chronic diseases.
Special Precautions
Avoid prolonged use and overdose, especially in children.
Effect on the ability to drive vehicles and mechanisms
When used in doses exceeding the recommended ones, a general effect on the cardiovascular system and central nervous system cannot be excluded. In such cases, a decrease in the ability to drive vehicles and engage in other potentially hazardous activities is possible.
Drug Interactions
With simultaneous use of MAO inhibitors and tricyclic antidepressants, an increase in blood pressure is possible.
Oxymetazoline slows down the absorption of local anesthetics and prolongs their action.
Concomitant use of other vasoconstrictor drugs increases the risk of side effects.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer